372 related articles for article (PubMed ID: 29888839)
1. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
3. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
4. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
5. The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy.
Ma Y; Bao X; Xiong F; Wang J; Gu N; Guo J; Wu H; Lu J
Cell Mol Biol (Noisy-le-grand); 2019 Feb; 65(2):75-81. PubMed ID: 30860474
[TBL] [Abstract][Full Text] [Related]
6. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.
Cao W; Li M; Zhang L; Lu Y; Wu S; Shen G; Chang M; Liu R; Gao Y; Hao H; Hu L; Yi W; Pan CQ; Xie Y
Biomed Res Int; 2021; 2021():2178143. PubMed ID: 33575322
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
8. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
9. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.
Micco L; Peppa D; Loggi E; Schurich A; Jefferson L; Cursaro C; Panno AM; Bernardi M; Brander C; Bihl F; Andreone P; Maini MK
J Hepatol; 2013 Feb; 58(2):225-33. PubMed ID: 23046671
[TBL] [Abstract][Full Text] [Related]
10. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
11. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
[TBL] [Abstract][Full Text] [Related]
12. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy.
Cao W; Lu H; Zhang L; Wang S; Deng W; Jiang T; Lin Y; Yang L; Bi X; Lu Y; Zhang L; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Hu L; Xie Y; Li M
Front Immunol; 2022; 13():1067362. PubMed ID: 36479104
[TBL] [Abstract][Full Text] [Related]
13. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
15. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.
Hagiwara S; Kudo M; Osaki Y; Matsuo H; Inuzuka T; Matsumoto A; Tanaka E; Sakurai T; Ueshima K; Inoue T; Yada N; Nishida N
J Med Virol; 2013 Jun; 85(6):987-95. PubMed ID: 23588724
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
[TBL] [Abstract][Full Text] [Related]
17. Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients.
Ning L; Huang X; Xu Y; Yang G; Yang J; Fu Q; Zhang Q; Liu H; Wu X; Wang Z; Luo K
J Interferon Cytokine Res; 2019 Dec; 39(12):740-751. PubMed ID: 31329012
[TBL] [Abstract][Full Text] [Related]
18. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.
Hagiwara S; Nishida N; Watanabe T; Ida H; Sakurai T; Ueshima K; Takita M; Komeda Y; Nishijima N; Osaki Y; Kudo M
Antivir Ther; 2018; 23(6):513-521. PubMed ID: 29438098
[TBL] [Abstract][Full Text] [Related]
19. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
20. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
